USDA Grants Full Approval for Novel Canine Parvovirus Therapy

USDA grants full approval for novel canine parvovirus therapy

Elanco's monoclonal antibody therapy, Trutect, received a conditional license from the federal agency in 2023.

Elanco Receives Full USDA Approval of Trutect (CPMA) Treatment for Deadly Canine Parvovirus

Elanco Animal Health today announced that its lifesaving treatment for the deadly canine parvovirus (parvo), Canine Parvovirus Monoclonal Antibody (CPMA), has received full approval from the U.S. Department of Agriculture (USDA) and will join Elanco’s Tru portfolio under the new brand name Trutect. Parvo is a devastating disease that affects more than 330,000 puppies annually, with up to a staggering 91% mortality rate without supportive care.[i…